Although a significant proportion of AML patients can now be cured, studies on newer treatment options such as the BCL-2 inhibitor venetoclax revealed that patients can become resistant to this drug, resulting in lower survival rates [96]. The gene discussed is BCL2; the disease is acute myeloid leukemia.